| TDP-43 — TAR DNA-Binding Protein 43 | |
|---|---|
| Full Name | TAR DNA-Binding Protein 43 |
| Gene | [TARDBP](/genes/tardbp) |
| UniProt | Q7J653 |
| Chromosome | 1p36 |
| Protein Type | RNA/DNA-binding protein (hnRNP family) |
| Molecular Weight | ~44 kDa (414 aa) |
| Key Diseases | [ALS](/diseases/als), [FTD](/diseases/ftd), [Alzheimer's](/diseases/alzheimers) |
| Key Mutations | |
| A382T, G348C, M337V, Q331K, G295S, D262G, N267S, K263E | |
TDP-43 (TAR DNA-Binding Protein 43) is a ubiquitously expressed RNA/DNA-binding protein encoded by the TARDBP gene on chromosome 1p36. It is a member of the hnRNP (heterogeneous nuclear ribonucleoprotein) family and plays essential roles in RNA processing, splicing, and stress response [1].
TDP-43 is central to the pathogenesis of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and is commonly co-detected in Alzheimer's disease as a secondary pathology. Over 95% of ALS cases and approximately 50% of FTD cases show TDP-43 inclusions, making it one of the most important protein aggregation diseases in neurodegeneration [2].
The discovery of TDP-43 as the major component of ubiquitin-positive inclusions in ALS and FTD in 2006 was a landmark in neurodegeneration research, unifying these previously distinct clinical entities under a common pathological mechanism [1:1]. This finding has led to intense research into understanding TDP-43's normal functions and how dysregulation leads to disease.
TDP-43 is a 414-amino-acid protein with three major functional domains that work together to enable its diverse cellular functions:
1 100 200 300 414
|----------|----------|----------|-----------|
| N-term | RRM1 | RRM2 | Gly-rich |
| Dimer | RNA binding | Low-complexity|
N-terminal domain (aa 1-102): The N-terminal domain is relatively structured and mediates protein dimerization. The dimerization of TDP-43 is essential for its function in assembling ribonucleoprotein complexes. Studies have shown that the N-terminal domain can form both homodimers and heterodimers with other hnRNP proteins [3]. This domain also contains the nuclear localization signal (NLS) and is involved in nuclear import through interaction with importin-alpha.
RNA Recognition Motifs (RRM1: aa 106-176, RRM2: aa 191-262):
C-terminal glycine-rich low-complexity domain (aa 274-414):
Cryo-EM studies have revealed that TDP-43 forms a dimer through interactions in the N-terminal domain, with the two RRM domains arranged in a dumbbell-like structure. The C-terminal domain is highly flexible and can adopt multiple conformations, which is relevant to its aggregation behavior. Recent studies have shown that TDP-43 aggregates in patient brains display conformational heterogeneity, suggesting distinct "strains" may underlie different clinical phenotypes [6].
TDP-43 pathology is characterized by several post-translational modifications that serve as disease biomarkers:
Phosphorylation: Pathological phosphorylation at Ser409/Ser410 is the hallmark of TDP-43 inclusions. This modification is mediated by casein kinase isoforms and is thought to promote aggregation while impairing degradation. Phospho-Ser409/410 antibodies are used diagnostically to detect TDP-43 pathology [7].
Ubiquitination: TDP-43 inclusions are ubiquitinated, marking them for proteasomal degradation. The ubiquitin ligase complex that modifies TDP-43 includes multiple enzymes, and ubiquitination may be both a cause and consequence of aggregation.
C-terminal fragmentation: Proteolytic cleavage generates C-terminal fragments (approximately 25-35 kDa) that are highly aggregation-prone. These fragments are detected in patient brains and cerebrospinal fluid, serving as potential biomarkers.
Acetylation: Acetylation at specific lysine residues in the RRM domains reduces RNA binding affinity and may contribute to loss-of-function in disease.
Sumoylation: SUMO conjugation has been reported to modulate TDP-43 aggregation and may influence its nuclear-cytoplasmic shuttling.
TDP-43 is predominantly nuclear in healthy cells, where it functions as a master regulator of RNA metabolism.
TDP-43 is a master regulator of RNA splicing with thousands of RNA targets [8]:
Cryptic exon repression: One of TDP-43's most critical functions is repressing the inclusion of cryptic exons in pre-mRNA transcripts. Loss of nuclear TDP-43 leads to aberrant inclusion of cryptic exons, particularly in transcripts involved in neuronal function. This results in premature termination codons and transcript degradation [9].
Long transcript stabilization: TDP-43 preferentially binds to long neuronal transcripts, many of which encode proteins involved in synaptic function, axonal guidance, and cytoskeletal organization. These transcripts are particularly vulnerable to TDP-43 loss-of-function.
Alternative splicing: TDP-43 regulates the alternative splicing of hundreds of genes, influencing isoform expression patterns. It can act as both an activator and repressor of specific splice sites, depending on binding location and context.
Synaptic program maintenance: TDP-43 controls the splicing of synaptic and cytoskeletal genes, ensuring proper expression of proteins required for neuronal connectivity and function.
Loss of nuclear TDP-43 causes widespread transcriptome disruption [4:1]:
Beyond splicing, TDP-43 participates in:
Under stress conditions or in disease, TDP-43 redistributes to the cytoplasm where it performs additional functions.
Under cellular stress, TDP-43 translocates to stress granules [10]:
TDP-43 participates in:
Emerging evidence shows TDP-43 has important nuclear functions in DNA repair [12]:
TDP-43 undergoes liquid-liquid phase separation (LLPS) through its C-terminal low-complexity domain [5:1]:
TDP-43 aggregation follows a characteristic pattern that defines the disease:
This sequence of events leads to both loss-of-function (nuclear) and gain-of-toxicity (cytoplasmic) mechanisms.
Three coupled processes drive ALS pathogenesis [4:2]:
Loss-of-function: Nuclear depletion impairs cryptic exon repression, leading to transcriptome dysregulation. This affects genes critical for neuronal survival and function.
Gain-of-toxicity: Cytoplasmic aggregates perturb proteostasis, stress granule dynamics, and mitochondrial function. The aggregates may also sequester essential proteins.
Network amplification: Glial dysfunction and neuroinflammation propagate pathology beyond initially affected neurons. Astrocytes and microglia adopt toxic phenotypes.
TDP-43 pathology in FTD shows distinct patterns:
FTLD-TDP subtypes A-D: Different anatomical patterns and pathological features characterize distinct subtypes. Subtype A shows neuronal cytoplasmic inclusions in layer II of the frontal cortex; subtype B shows widespread neuronal inclusions; subtype C shows neuronal intranuclear inclusions; subtype D shows dense inclusions in motor neurons.
Behavioral variant FTD: Executive and social-cognitive impairment due to frontotemporal network degeneration
Primary progressive aphasia: Language network degeneration, particularly affecting the left perisylvian region
ALS-FTD overlap: Combined motor and cognitive phenotypes represent a disease spectrum
TDP-43 is frequently detected in AD brains [13]:
Recent research shows that TDP-43 pathology spreads through neural circuits [15]:
TDP-43 pathology is also seen in:
Antisense oligonucleotides (ASOs): Several ASOs targeting TARDBP mRNA have entered clinical trials. These reduce mutant TDP-43 expression while sparing wild-type. Current trials focus on reducing all TDP-43, as complete loss is not viable [17].
RNA-binding modifiers: Small molecules that alter TDP-43-RNA interactions could restore proper splicing function
Aggregation inhibitors: Block C-terminal aggregation through stabilization of native state or blocking amyloid formation
Phase separation modulators: Targeting the LLPS behavior of TDP-43 could prevent pathological aggregation
Proteasome enhancers: Improve clearance of misfolded TDP-43 and aggregates
Autophagy modulators: Enhance autophagy to clear inclusions. The lysosomal pathway is impaired in TDP-43 proteinopathy [@chiu2019].
Integrated stress response: Modulate ISR pathways that are activated in TDP-43 depletion
Molecular chaperones: Enhance chaperone activity to prevent aggregation
Neuroinflammation reduction: Target glial activation and reduce inflammatory cytokine release [18]
Synaptic protection: Preserve synaptic function and prevent dendritic loss
Metabolic support: Maintain energy homeostasis in affected neurons
Neurotrophic factors: Support neuron survival and regeneration
Over 50 pathogenic mutations in TARDBP have been identified, predominantly in the C-terminal domain [19]:
| Mutation | Location | Effect | Clinical Phenotype |
|---|---|---|---|
| A382T | C-terminal | Most common, ~50% of TARDBP ALS | ALS/FTD |
| M337V | C-terminal | Aggressive ALS, early onset | ALS |
| Q331K | C-terminal | ALS with dementia | ALS-FTD |
| G348C | C-terminal | FTD predominant | FTD |
| G295S | C-terminal | Classic ALS | ALS |
| D262G | C-terminal | ALS | ALS |
| N267S | C-terminal | Variable penetrance | ALS/FTD |
| K263E | C-terminal | ALS | ALS |
| A90K | N-terminal | Reduced penetrance | ALS |
Both familial and sporadic ALS/FTD show TDP-43 pathology:
TDP-43 interacts with numerous proteins that modulate its function [8:1]:
| Partner | Interaction | Functional Effect |
|---|---|---|
| FUS | Co-aggregation | ALS spectrum, shared mechanisms |
| TIA1 | Stress granules | Stress response regulation |
| hnRNPs (A1, A2, A3) | Splicing complex | RNA processing |
| UBQLN2 | Autophagy | Protein clearance |
| p62 | Inclusion bodies | Degradation, selective autophagy |
| OPTN | Mitophagy | Mitochondrial quality control |
| VCP | Degradation | Proteostasis regulation |
| G3BP1 | Stress granules | Stress response |
| HDAC6 | Transport | Aggresome formation |
TDP-43 influences multiple signaling pathways:
Beyond mRNA, TDP-43 binds:
TDP-43 in ALS and FTD. Nature. 2006. ↩︎ ↩︎ ↩︎
Pathological TDP-43 in neurodegenerative diseases. Acta Neuropathologica. 2009. ↩︎ ↩︎ ↩︎
Nuclear import of TDP-43 is mediated by importin-alpha. Journal of Biological Chemistry. 2020. ↩︎
TDP-43 and ALS: genetic and molecular insights. Cell. 2019. ↩︎ ↩︎ ↩︎ ↩︎
TDP-43 phase separation and aggregation in neurodegeneration. Nature Reviews Molecular Cell Biology. 2023. ↩︎ ↩︎ ↩︎
TDP-43 aggregates in the brain of ALS patients show conformational heterogeneity. Nature Neuroscience. 2024. ↩︎
TDP-43 post-translational modifications in disease. Acta Neuropathologica Communications. 2022. ↩︎
TDP-43 functions in RNA metabolism and alternative splicing. Nature Reviews Neuroscience. 2020. ↩︎ ↩︎ ↩︎
Cryptic exon inclusion in TDP-43 depletion models. Cell Reports. 2023. ↩︎
TDP-43 stress granules in neurodegeneration. Trends in Cell Biology. 2019. ↩︎ ↩︎
TDP-43 and stress granules in cellular models of ALS. Brain. 2022. ↩︎
The role of TDP-43 in mitochondrial dysfunction in ALS. Journal of Molecular Biology. 2018. ↩︎ ↩︎
TDP-43 pathology in Alzheimer's disease. Nature Reviews Neurology. 2019. ↩︎ ↩︎
LATE-NC: Limbic-predominant age-related TDP-43 encephalopathy. Brain. 2019. ↩︎ ↩︎ ↩︎
TDP-43 pathology spreads through neural circuits. Brain. 2024. ↩︎
Novel TARDBP mutations in ALS patients. Neurology. 2024. ↩︎
Therapeutic strategies targeting TDP-43 in ALS/FTD. Molecular Therapy. 2023. ↩︎
TDP-43 drives neuroinflammation in ALS/FTD. GLIA. 2023. ↩︎
TARDBP mutations in ALS. Neurobiology of Aging. 2020. ↩︎ ↩︎